Substance Use and Addiction: From Molecular Mechanisms to Treatment

A Special Issue of Brain Sciences (ISSN 2076-3425) belonging to the section "Neuropharmacology and Neuropathology".

Deadline for manuscript submissions: 25 February 2027 | Viewed by 1137

Editors


E-Mail Website
Guest Editor
Department of Neurosciences, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Florence, 50121 Florence, Italy
Interests: psychopathology; mental health; clinical toxicology; new psychoactive substances; drug misuse; addiction; craving
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Substance use disorders constitute a critical global health challenge. The term "substance", from the Latin "substantia", has evolved over time, with a variety of ontological (what is it?), epistemological (how can we know it?), and metaphysical (what role does it play?) implications. Within neuroscientific and medical contexts, “substances” refer to psychoactive agents that physiologically alter mental states, and these compounds have been studied progressively in relation to use disorders, distinguished between therapeutic, recreational, and pathological patterns. Understanding these conditions requires examination of the reward circuitry—particularly the mesolimbic dopaminergic pathways—and neuroadaptive mechanisms, including receptor desensitization, synaptic remodeling, and tolerance development. 

Multidisciplinary investigation across molecular, cellular, and system levels reveals dysregulation of neurotransmitter systems, neuroplasticity, neuroinflammatory processes, and glial contributions within reward and executive control circuits. Interactions between genetic vulnerability, environmental factors, and disrupted prefrontal–limbic connectivity drive the transition from recreational to compulsive use. These insights inform therapeutic strategies, combining pharmacological interventions (agonists/antagonist therapies, novel agents targeting glutamatergic, neuroimmune/neuroendocrine pathways), neuromodulation, and biomarker-driven precision medicine, integrated with psychosocial interventions. 

Nonetheless, critical challenges persist. Limited treatment efficacy and a high relapse rate reflect inadequate clinical translation. Advancing detailed mechanistic understanding may enhance personalized paradigms. Thus, the aim of this Special Issue is to bridge knowledge gaps through integrative translational frameworks addressing substance use disorders. 

In this Special Issue, we invite submissions of original research manuscripts, reviews and meta-analyses, case reports, brief reports, opinions, and perspectives.

Dr. Davide Arillotta
Dr. Giuseppe Floresta
Prof. Dr. Fabrizio Schifano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • substance use disorders
  • addiction
  • reward
  • neuroplasticity
  • craving
  • precision medicine
  • translational neuroscience
  • co-occurring substance use and mental disorders

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 1234 KB  
Article
Non-Psychoactive Cannabis Extract Disrupts Reinstatement and Reconsolidation in Cocaine-Induced Conditioned Place Preference in Mice
by Fabián Leonardo Barreto, María Constanza Lozano, Yoshie Adriana Hata, Aura Rocio Hernández and Jorge A. Martínez-Ramírez
Brain Sci. 2026, 16(6), 585; https://doi.org/10.3390/brainsci16060585 - 29 May 2026
Viewed by 498
Abstract
Background: Cocaine use disorder (CUD) remains a major global health concern, with no FDA-approved pharmacological treatments currently available. Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa L., has shown promising preclinical effects in disrupting the consolidation and retrieval of drug-associated memories, thereby [...] Read more.
Background: Cocaine use disorder (CUD) remains a major global health concern, with no FDA-approved pharmacological treatments currently available. Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa L., has shown promising preclinical effects in disrupting the consolidation and retrieval of drug-associated memories, thereby attenuating relapse-like behaviors. Objectives: The present study evaluated the effects of a low-THC CBD-rich cannabis extract (NPCE) on the reinstatement and reconsolidation of cocaine-induced conditioned place preference (CPP) in male CD1 (ICR) mice, an approach not previously investigated. Methods: The extract was administered at a dose equivalent to 20 mg/kg of CBD. Treatment significantly attenuated both priming- and stress-induced reinstatement of cocaine-induced CPP. Reinstatement was triggered either by a cocaine priming injection or by acute stress exposure, whereas reconsolidation-like processes were assessed by administering the extract following memory reactivation sessions and subsequently evaluating the persistence of cocaine-associated preference over time. Results: NPCE showed a consistent result with disruption of reconsolidation-like processes of cocaine-associated memory, with effects persisting for at least two weeks. The extract alone did not induce conditioned preference or aversion. Conclusions: These findings suggest that NPCE modulates drug-associated memory processes involved in relapse-like behavior. However, the underlying mechanisms were not directly evaluated and remain to be elucidated. Further studies are warranted to include both sexes, evaluate effects across multiple behavioral paradigms, directly compare full-spectrum extracts with isolated cannabinoids, and incorporate receptor-specific approaches to clarify the mechanisms of action. Full article
(This article belongs to the Special Issue Substance Use and Addiction: From Molecular Mechanisms to Treatment)
Show Figures

Figure 1

Back to TopTop